Wim Wuyts

Wim Wuyts

Auto-generated profile, based on publicly available information

Wim Wuyts

Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2001 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
WBW Balemans
W Balemans
MEM Ebeling
M Ebeling
NPN Patel
N Patel
EHE Van Hul
E Van Hul
POP Olson
P Olson
WHWim Van Hul
Wim Van Hul
Sclerosteosis is a progressive sclerosing bone dysplasia with an autosomal recessive mode of inheritance. Radiologically, it is characterized by a generalized hyperostosis and sclerosis leading to a markedly thickened and sclerotic skull, with mandible, ribs, clavicles and all long bones also being affected. Due to narrowing of the foramina of the cranial nerves, facial nerve palsy, hearing loss and atrophy of the optic nerves can occur. Sclerosteosis is clinically and radiologically very similar to van Buchem disease, mainly differentiated by hand malformations and a large stature in sclerosteosis patients. By linkage analysis in one extended van Buchem family and two consanguineous sclerosteosis families we previously mapped both disease genes to the same chromosomal 17q12–q21 region, supporting the hypothesis that both conditions are caused by mutations in the same gene. After reducing the disease critical region to ~1 Mb, we used the positional cloning strategy to identify the SOST gene, which is mutated in sclerosteosis patients. This new gene encodes a protein with a signal peptide for secretion and a cysteine-knot motif. Two nonsense mutations and one splice site mutation were identified in sclerosteosis patients, but no mutations were found in a fourth sclerosteosis patient nor in the patients from the van Buchem family. As the three disease-causing mutations lead to loss of function of the SOST protein resulting in the formation of massive amounts of normal bone throughout life, the physiological role of SOST is most likely the suppression of bone formation. Therefore, this gene might become an important tool in the development of therapeutic strategies for osteoporosis.

1 February 2002 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
WBW Balemans
W Balemans
NPN Patel
N Patel
MEM Ebeling
M Ebeling
EHE Van Hul
E Van Hul
WWW Wuyts
W Wuyts
WHWim Van Hul
Wim Van Hul
Van Buchem disease is an autosomal recessive skeletal dysplasia characterised by generalised bone overgrowth, predominantly in the skull and mandible. Clinical complications including facial nerve palsy, optic atrophy, and impaired hearing occur in most patients. These features are very similar to those of sclerosteosis and the two conditions are only differentiated by the hand malformations and the tall stature appearing in sclerosteosis. Using an extended Dutch inbred van Buchem family and two inbred sclerosteosis families, we mapped both disease genes to the same region on chromosome 17q12-q21, supporting the hypothesis that van Buchem disease and sclerosteosis are caused by mutations in the same gene. In a previous study, we positionally cloned a novel gene, called SOST, from the linkage interval and identified three different, homozygous mutations in the SOST gene in sclerosteosis patients leading to loss of function of the underlying protein. The present study focuses on the identification of a 52 kb deletion in all patients from the van Buchem family. The deletion, which results from a homologous recombination between Alu sequences, starts approximately 35 kb downstream of the SOST gene. Since no evidence was found for the presence of a gene within the deleted region, we hypothesise that the presence of the deletion leads to a down regulation of the transcription of the SOST gene by a cis regulatory action or a position effect.

15 October 2002 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
LHLynne J. Hocking
Lynne J. Hocking
GLGavin J.A. Lucas
Gavin J.A. Lucas
ADAnna Daroszewska
Anna Daroszewska
JMJon Mangion
Jon Mangion
MOMark Olavesen
Mark Olavesen
SRStuart H. Ralston
Stuart H. Ralston
Paget's disease of bone (PDB) is a common disorder characterized by focal abnormalities of increased and disorganized bone turnover. Genetic factors are important in the pathogenesis of PDB, and in previous studies, we and others identified a locus for familial PDB by genome-wide search on 5q35-qter (PDB3). The gene encoding sequestosome 1 (SQSTM1/p62) maps to within the PDB3 critical region, and recent studies have identified a proline–leucine amino acid change at codon 392 of SQSTM1 (P392L) in French-Canadian patients with PDB. We conducted mutation screening of positional candidate genes in the PDB3 locus in patients with PDB, and also identified mutations in the gene encoding SQSTM1 as a common cause of familial and sporadic PDB. Three different mutations were found, all affecting the highly conserved ubiquitin-binding domain. The most common mutation was the P392L change in exon 8, which was found in 13 of 68 families (19.1%). Another mutation—a T insertion that introduces a stop codon at position 396 in exon 8—was found in four (5.8%) families. A third mutation affecting the splice donor site in intron 7 was found in one (1.5%) family. The P392L mutation was also found in 15 of 168 (8.9%) of patients with sporadic PDB and 0 of 160 of age- and sex-matched controls (P<0.0001). These studies confirm that mutations affecting the ubiquitin-binding domain of SQSTM1 are a common cause of familial and sporadic Paget's disease of bone.

1 July 2005 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
Ignacio del CastilloIgnacio del Castillo
Ignacio del Castillo
MRM Rodríguez-Ballesteros
M Rodríguez-Ballesteros
AÁA Álvarez
A Álvarez
THT Hutchin
T Hutchin
ELEmanuela LEONARDI
Emanuela LEONARDI
Ignacio del CastilloIgnacio del Castillo
Ignacio del Castillo
In many populations, up to 50% of all cases of ARNSHI are caused by mutations in the DFNB1 locus (MIM 220290) on 13q12.4 This locus contains the GJB2 gene (MIM 121011), encoding connexin-26 (Cx26),5 which belongs to a family of transmembrane proteins with about 20 members in humans. Hexamers of connexins (connexons) are displayed in the plasma membrane. Docking of connexons on the surfaces of two adjacent cells results in the formation of intercellular gap junction channels.6 Several different connexins, including Cx26, have been shown to participate in the complex gap junction networks of the cochlea.7, 8 It has been postulated that these networks play a key role in potassium homeostasis, which is essential for the sound transduction mechanism.9

1 December 2003 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
Ignacio del CastilloIgnacio del Castillo
Ignacio del Castillo
MMMiguel A. Moreno-Pelayo
Miguel A. Moreno-Pelayo
Ignacio del CastilloIgnacio del Castillo
Ignacio del Castillo
ZBZippora Brownstein
Zippora Brownstein
SMSandrine Marlin
Sandrine Marlin
FMFelipe Moreno
Felipe Moreno

1 December 2009 in Human Mutation
Verified
Journal Article
Closed access
PDF file
IJIvy Jennes
Ivy Jennes
EPElena Pedrini
Elena Pedrini
MZMonia Zuntini
Monia Zuntini
MMMarina Mordenti
Marina Mordenti
SBSahila Balkassmi
Sahila Balkassmi
WWWim Wuyts
Wim Wuyts
Multiple osteochondromas (MO) is an autosomal dominant skeletal disease characterized by the formation of multiple cartilage‐capped bone tumors growing outward from the metaphyses of long tubular bones. MO is genetically heterogeneous, and is associated with mutations in Exostosin‐1 (EXT1) or Exostosin‐2 (EXT2), both tumor‐suppressor genes of the EXT gene family. All members of this multigene family encode glycosyltransferases involved in the adhesion and/or polymerization of heparin sulfate (HS) chains at HS proteoglycans (HSPGs). HSPGs have been shown to play a role in the diffusion of Ihh, thereby regulating chondrocyte proliferation and differentiation. EXT1 is located at 8q24.11–q24.13, and comprises 11 exons, whereas the 16 exon EXT2 is located at 11p12–p11. To date, an EXT1 or EXT2 mutation is detected in 70–95% of affected individuals. EXT1 mutations are detected in ±65% of cases, versus ±35% EXT2 mutations in MO patient cohorts. Inactivating mutations (nonsense, frame shift, and splice‐site mutations) represent the majority of MO causing mutations (75–80%). In this article, the clinical aspects and molecular genetics of EXT1 and EXT2 are reviewed together with 895 variants in MO patients. An overview of the reported variants is provided by the online Multiple Osteochondromas Mutation Database (http://medgen.ua.ac.be/LOVD). Hum Mutat 30:1–8, 2009.